BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
21 hedge funds and large institutions have $4.39M invested in BRAINSTORM CELL THERAPUTC in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 2 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
43% more call options, than puts
Call options by funds: $43K | Put options by funds: $30K
5% more funds holding
Funds holding: 20 → 21 (+1)
32% less capital invested
Capital invested by funds: $6.48M → $4.39M (-$2.09M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$341K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$100K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$18.8K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$15.1K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$5.59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$106K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$3.67K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$1.55K |
BCLI Hedge Fund Activity: Q3 2015 in Review
21 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2015, worth a combined $4.39M — down 32% from $6.48M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BCLI positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, adding an estimated $341K. The largest seller was TFS Capital, exiting entirely with an estimated $106K sold.
- 21 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2015, up from 20 in Q2 2015.
- Funds reported $4.39M of BRAINSTORM CELL THERAPUTC stock for Q3 2015, down 32% quarter-over-quarter.
- 3 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2015 and 2 closed out, a net change of +1 holder.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2015 was Sabby Management, an estimated $341K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q3 2015 was TFS Capital, an estimated $106K sold.
Based on aggregated 13F filings for Q3 2015.